Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases
David S. Goldstein, Mark J. Pekker, Graeme Eisenhofer, Yehonatan Sharabi
David S. Goldstein, Mark J. Pekker, Graeme Eisenhofer, Yehonatan Sharabi
View: Text | PDF
Clinical Research and Public Health Cardiology Neuroscience

Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases

  • Text
  • PDF
Abstract

BACKGROUND Lewy body diseases, a family of aging-related neurodegenerative disorders, entail loss of the catecholamine dopamine in the nigrostriatal system and equally severe deficiency of the closely related catecholamine norepinephrine in the heart. The myocardial noradrenergic lesion is associated with major nonmotor symptoms and decreased survival. Numerous mechanisms determine norepinephrine stores, and which of these are altered in Lewy body diseases has not been examined in an integrated way. We used a computational modeling approach to assess comprehensively pathways of cardiac norepinephrine synthesis, storage, release, reuptake, and metabolism in Lewy body diseases. Application of a potentially novel kinetic model identified a pattern of dysfunctional steps contributing to norepinephrine deficiency. We then tested predictions from the model in a new cohort of Parkinson disease patients.METHODS Rate constants were calculated for 17 reactions determining intraneuronal norepinephrine stores. Model predictions were tested by measuring postmortem apical ventricular concentrations and concentration ratios of catechols in controls and patients with Parkinson disease.RESULTS The model identified low rate constants for 3 types of processes in the Lewy body group: catecholamine biosynthesis via tyrosine hydroxylase and aromatic l-amino acid decarboxylase, vesicular storage of dopamine and norepinephrine, and neuronal norepinephrine reuptake via the cell membrane norepinephrine transporter. Postmortem catechols and catechol ratios confirmed this triad of model-predicted functional abnormalities.CONCLUSION Denervation-independent impairments of neurotransmitter biosynthesis, vesicular sequestration, and norepinephrine recycling contribute to the myocardial norepinephrine deficiency attending Lewy body diseases. A proportion of cardiac sympathetic nerves are “sick but not dead,” suggesting targeted disease modification strategies might retard clinical progression.FUNDING Division of Intramural Research, NINDS.

Authors

David S. Goldstein, Mark J. Pekker, Graeme Eisenhofer, Yehonatan Sharabi

×

Figure 1

Concept diagram depicting steps of catecholamine synthesis, storage, release, recycling, and metabolism in myocardial sympathetic nerves.

Options: View larger image (or click on image) Download as PowerPoint
Concept diagram depicting steps of catecholamine synthesis, storage, rel...
Reactions are in italics and amounts of reactants in plain text. Font sizes correspond roughly to amounts of reactants. Green arrows indicate dopamine (DA) synthesis and blue arrows norepinephrine (NE) vesicular uptake and leakage. After tyrosine (TYR) uptake, cytoplasmic TYR (TYRc) is converted to 3,4-dihydroxyphenylalanine (DOPA) via tyrosine hydroxylase (TH). Cytoplasmic DOPA (DOPAc) is converted to DA via aromatic l-amino acid decarboxylase (LAAAD) or undergoes spontaneous oxidation to form 5-S-cysteinyldopa (Cys-DOPA). Cytoplasmic DA (DAc) is converted to 3,4-dihydroxyphenylacetaldehyde (DOPAL) via monoamine oxidase (MAO), undergoes spontaneous oxidation to form 5-S-cysteinylDA, or is taken up into vesicles via the vesicular monoamine transporter (VMAT). DOPAL is metabolized by aldehyde dehydrogenase (ALDH) to form 3,4-dihydroxyphenylacetic acid (DOPAC) or by aldehyde/aldose reductase (AR) to form 3,4-dihydroxyphenylethanol. DA in vesicles is converted to NE via dopamine-β-hydroxylase (DBH) or leaks passively into the cytoplasm. NE in vesicles is released into the extracellular fluid or leaks passively into the cytoplasm. Cytoplasmic NE (NEc) is converted to 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) via MAO, and DOPEGAL is metabolized to 3,4-dihydroxyphenylglycol (DHPG) via AR. NE in the extracellular fluid (NEe) is taken up into the nerve by Uptake-1 (U1), spills over into the cardiac venous drainage, or is removed by extraneuronal uptake (Uptake-2). Circulating epinephrine (EPI) can be taken up into the nerve by U1 and transported into vesicles via the VMAT.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts